Andreas Lundqvist's Group

Our research focuses to understand mechanisms of immune escape in solid tumors.

Andreas Lundqvist's research group.

The immune system plays an important role to prevent local growth and dissemination of cancer. Therapies based on activating the immune system can result in beneficial responses in patients with cancer. In order to harness the full potential of the immune system T and NK cells need to colonize tumors as well as to display optimal tumor killing potential. We investigate the ability of T and NK cells to migrate towards tumors, to persist within the tumor microenvironment, and to maintain the ability to and recognize and kill tumor cells. We study how T and NK cells interact with cells within the tumor microenvironment and exploit cellular and molecular mechanisms of tumor-induced immunosuppression to develop improved immunotherapy regimens in patients with cancer.

Group members

Andreas Lundqvist, Group leader, Professor
Neda Bigdeli, Biomedical Scientist
Mireia Cruz de los Santos, PhD student
Apple Tay, PhD student
Le Tong, PhD student
Lisa Liu, Affiliated to research
Ying Yang, post-doc


Erik Wennerberg, The Institute of Cancer Research, London
Dhifaf Sarhan, Karolinska Institutet
Veronika Kremer, ‎Novartis
Kristina Witt, Oncopeptides
Maria Wolodarski, Karolinska University Hospital
Ziqing Chen, Princeton University
Shi Yong Neo, Agency for Science, Technology and Research (A*STAR), Singapore
Khang Luu, National University of Singapore

Selected publications

Tumor MHC class I expression alters cancer-associated myelopoiesis driven by host NK cells.
Neo SY, Jing X, Tong L, Tong D, Gao J, Chen Z, De Los Santos MC, Burduli N, De Souza Ferreira S, Wagner AK, Alici E, Rolny C, Cao Y, Lundqvist A
J Immunother Cancer 2022 Oct;10(10):

A2B adenosine receptor antagonists rescue lymphocyte activity in adenosine-producing patient-derived cancer models.
Tay AHM, Prieto-Díaz R, Neo S, Tong L, Chen X, Carannante V, Önfelt B, Hartman J, Haglund F, Majellaro M, Azuaje J, Garcia-Mera X, Brea JM, Loza MI, Jespers W, Gutierrez-de-Teran H, Sotelo E, Lundqvist A
J Immunother Cancer 2022 May;10(5):

B7-H7 Is Inducible on T Cells to Regulate Their Immune Response and Serves as a Marker for Exhaustion.
Luu K, Schwarz H, Lundqvist A
Front Immunol 2021 ;12():682627

Phosphodiesterase 4A confers resistance to PGE2-mediated suppression in CD25+ /CD54+ NK cells.
Chen Z, Yang Y, Neo SY, Shi H, Chen Y, Wagner AK, Larsson K, Tong L, Jakobsson PJ, Alici E, Wu J, Cao Y, Wang K, Liu LL, Mao Y, Sarhan D, Lundqvist A
EMBO Rep 2021 Jan;():e51329

Thioredoxin activity confers resistance against oxidative stress in tumor-infiltrating NK cells.
Yang Y, Neo SY, Chen Z, Cui W, Chen Y, Guo M, Wang Y, Xu H, Kurzay A, Alici E, Holmgren L, Haglund F, Wang K, Lundqvist A
J Clin Invest 2020 10;130(10):5508-5522

CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment.
Neo SY, Yang Y, Record J, Ma R, Chen X, Chen Z, Tobin NP, Blake E, Seitz C, Thomas R, Wagner AK, Andersson J, de Boniface J, Bergh J, Murray S, Alici E, Childs R, Johansson M, Westerberg LS, Haglund F, Hartman J, Lundqvist A
J Clin Invest 2020 03;130(3):1185-1198

Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma.
Kremer V, Ligtenberg MA, Zendehdel R, Seitz C, Duivenvoorden A, Wennerberg E, Colón E, Scherman-Plogell AH, Lundqvist A
J Immunother Cancer 2017 09;5(1):73

Zoledronic acid inhibits NFAT and IL-2 signaling pathways in regulatory T cells and diminishes their suppressive function in patients with metastatic cancer.
Sarhan D, Leijonhufvud C, Murray S, Witt K, Seitz C, Wallerius M, Xie H, Ullén A, Harmenberg U, Lidbrink E, Rolny C, Andersson J, Lundqvist A
Oncoimmunology ;6(8):e1338238

IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells.
Mao Y, van Hoef V, Zhang X, Wennerberg E, Lorent J, Witt K, Masvidal L, Liang S, Murray S, Larsson O, Kiessling R, Lundqvist A
Blood 2016 09;128(11):1475-89

Dendritic cell regulation of NK-cell responses involves lymphotoxin-α, IL-12, and TGF-β.
Sarhan D, Palma M, Mao Y, Adamson L, Kiessling R, Mellstedt H, Österborg A, Lundqvist A
Eur J Immunol 2015 Jun;45(6):1783-93

List of all publications.

Current Research Funding

  • The Swedish Cancer Society
  • The Cancer Research Funds of Radiumhemmet
  • The Swedish Childhood Cancer Foundation
  • The Swedish Research Council